ImmuPharma (IMM) Share Price, News & Analysis

Company Overview

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidates include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations, a fungal infection caused by the aspergillus family of fungi; and BioCin, a peptide-based antibacterial drug used in high medical need cases and in last line of defense. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.

Key Stats

• Today's Range: 1.54 to 1.60
• 50-Day Range: 1.55 to 1.97
• 52-Week Range: 0.82 to 3
• Volume: 653,403 shs
• Average Volume: 1.74 million shs
• Market Capitalization: £6.52 million
• P/E Ratio: N/A
• Dividend Yield: 0.77%
• Price Target: N/A
• Consensus Rating: N/A

IMM Stock Analysis - Frequently Asked Questions

How have IMM shares performed this year?

ImmuPharma's stock was trading at GBX 1.67 at the start of the year. Since then, IMM shares have decreased by 6.2% and is now trading at GBX 1.57.
View the best growth stocks for 2024 here.

How were ImmuPharma's earnings last quarter?

ImmuPharma plc (LON:IMM) announced its quarterly earnings data on Wednesday, September, 30th. The company reported ($1.69) earnings per share (EPS) for the quarter.

How do I buy shares of ImmuPharma?

Shares of IMM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of ImmuPharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ImmuPharma investors own include Castleton Technology (CTP), 4D pharma (DDDD), MOTIF BIO PLC/S (MTFB), Nikola (NKLA), Thor Energy (THR), Aminex (AEX) and GSK (GSK).

Company Calendar

• Last Earnings: 9/30/2020
• Today: 11/23/2024

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:IMM
• CUSIP: N/A
• CIK: N/A
• Web: www.immupharma.org
• Phone: +44-20-71524080
• Fax: N/A
• Employees: 13
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-2,460,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -111.20%
• Return on Assets: -43.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.60
• Quick Ratio: 1.03

Sales & Book Value

• Annual Sales: £94,819.00
• Price / Sales: 68.73
• Cash Flow: GBX 0.08 per share
• Price / Cash Flow: 20.50
• Book Value: GBX 1 per share
• Price / Book: 1.57

Miscellaneous

• Outstanding Shares: 416,440,000
• Free Float: N/A
• Market Cap: £6.52 million
• Optionable: Not Optionable
• Beta: 1.53